TheNote
Blenrep shows significant over... Note
GooglePlay AppStore
GSK press releases

Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse

DREAMM-7 trial shows sustained overall survival benefit for Blenrep (belantamab mafodotin) combination versus daratumumab combination
https://www.gsk.com/en-gb/media/press-releases/blenrep-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse/ gsk.com
RSS Hunter RSS Hunter • Dec 9, 2024

Cookies help us deliver our Services. By using our Services or clicking I agree, you agree to our use of cookies .